Several biomarkers, such as PD-1/PD-L1 expression on tumor cells, T-cell infiltration within the tumor microenvironment, and tumor mutation burden (TMB) (6–8), have been proposed to be associated with the therapeutic response of NSCLC to immunotherapy. Here, CD274 is linked to neoplasm.